Noninvasive Prenatal Diagnosis of Fetal Chromosomal Abnormalities

Noninvasive prenatal diagnosis harnesses fragments of fetal DNA circulating in maternal blood to screen for chromosomal abnormalities without the risks associated with invasive sampling. Since the discovery of cell-free fetal DNA (cffDNA) in maternal plasma, advances in sequencing and bioinformatics have enabled highly accurate detection of common trisomies, including Down (trisomy 21), Edwards (trisomy 18) and Patau (trisomy 13) syndromes, as well as sex-chromosome anomalies. These techniques typically employ massively parallel sequencing or targeted assays to quantify chromosomal representation in a maternal blood sample as early as the first trimester. The approach drastically reduces procedure-related miscarriage rates by supplanting amniocentesis and chorionic villus sampling in many high-risk pregnancies. Beyond whole-chromosome aneuploidies, emerging applications include the detection of subchromosomal deletions and duplications, refining risk assessment for microdeletion syndromes and rare copy-number variants. The global uptake of noninvasive testing has reshaped prenatal care pathways, offering earlier and safer stratification of risk, improved counselling and informed decision-making for expectant parents.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Noninvasive Prenatal Diagnosis of Fetal Chromosomal Abnormalities publication trend

The graph below shows the total number of articles in noninvasive prenatal diagnosis of fetal chromosomal abnormalities across all publications each year (not limited to Nature Index journals).

Technical terms

Cell-free DNA: Fragments of fetal and maternal DNA circulating freely in the maternal bloodstream.

Aneuploidy: A chromosomal abnormality characterised by an atypical number of chromosomes in the genome.

Sensitivity: The proportion of true positive cases correctly identified by a diagnostic test.

Specificity: The proportion of true negative cases correctly excluded by a diagnostic test.

Positive predictive value: The probability that a positive test result corresponds to an actual chromosomal abnormality.

Copy number variation: A structural genomic alteration involving deletion or duplication of DNA segments.

Massively parallel sequencing: A high-throughput method that sequences millions of DNA fragments simultaneously to quantify genomic representation.

References

1. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open (2016).
2. Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down’s syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units. The BMJ (2016).
3. Noninvasive prenatal testing for chromosome aneuploidies and subchromosomal microdeletions/microduplications in a cohort of 42,910 single pregnancies with different clinical features. Human Genomics (2019).